In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on OncoMed Pharma (OMED), with a price target of $2. The company’s shares closed on Friday at $1.59, close to its 52-week low of $1.52.
According to TipRanks.com, White is a 5-star analyst with an average return of 13.9% and a 45.3% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for OncoMed Pharma with a $2 average price target.
See today’s analyst top recommended stocks >>
OncoMed Pharma’s market cap is currently $61.26M and has a P/E ratio of 10.01. The company has a Price to Book ratio of 1.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer’s growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.
